Physician profile
Abdul Q Malik
NPI 1215923685
$8,404.97
in general payments reported to CMS, 2019-2025
30 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $788 · 2021: $1,186 · 2022: $955 · 2023: $3,025 · 2024: $1,165 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105 · Long Term Medical Supply Or Device Loan: $1,788 · Travel and Lodging: $66.50 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.59 |
| Long Term Medical Supply Or Device Loan | $1,788.00 |
| Travel and Lodging | $66.50 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $1,788.00 | 2023 | Hillrom - Cp 150 Resting Electrocardiograph |
| Janssen Pharmaceuticals, INC | $1,106.49 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $691.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $624.14 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $532.05 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $471.83 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $435.10 | 2019-2025 | Verquvo, Capvaxive, Steglatro |
| Medtronic, INC. | $434.96 | 2021-2023 | Corevalve Evolut R, Cg Future, Linq II |
| Welch Allyn | $407.34 | 2020 | |
| Phathom Pharmaceuticals, INC. | $235.88 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $212.96 | 2020-2025 | |
| Cvrx, INC. | $210.88 | 2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $177.31 | 2019-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $159.23 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $143.24 | 2021-2024 | Trelegy Ellipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $131.26 | 2019-2022 | |
| Horizon Therapeutics Plc | $115.02 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $90.73 | 2024 | Assure Wcd |
| Biotronik INC. | $85.57 | 2019-2024 | Amvia Edge |
| Pfizer INC. | $69.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.29 | 2019 | |
| Shield Therapeutics INC | $43.05 | 2023 | Accrufer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.51 | 2019 | |
| Abiomed | $25.92 | 2025 | |
| Boston Scientific Corporation | $22.68 | 2024 | Watchman Flx |
| Alk-Abello, INC | $20.94 | 2025 | Neffy |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.52 | 2019 | |
| Abbott Laboratories | $18.41 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.06 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.